Ethics and participants
cardiac conduction block, liver dysfunction, diabetic neuropathy
CARDIAC ISCHEMIA, DIABETIC NEUROPATHY, HYPERTENSION, NEUROMUSCULAR DISEASE
This randomized controlled study was conducted at Affiliated Hospital of North Sichuan Medical College between January 2023 and February 2023, and was approved by the Ethics Committee of Affiliated Hospital of North Sichuan Medical College(2022ER494-1). All methods are in line with the relevant guidelines and regulations of the study. Written informed consent was obtained from all participants aged 18–65 years old who were scheduled for radical mastectomy and had an ASA physical status of I or II. The following were the exclusion criteria: hypertension, cardiac ischemia, history of cardiac conduction block, history of neuromuscular disease, pregnancy, chronic treatment with calcium channel blockers, liver dysfunction, diabetic neuropathy or known to hypersensitive to magnesium compounds. Patients who declined to participant were also excluded. All participants were randomly assigned to one of two parallel groups of equal size, with one group receiving intraoperative magnesium (the magnesium group) and the other group receiving saline (the control group).